So I am going to share some information with you guy's despite my general distaste for these boards as of late (too many personal attacks and negative posts all the time).
They already have positive clinical data in chronic kidney disease patients (a small 4 patient feasibility trial) that sought to evaluate the potential ability of PEMF to reduce proteinuria in CKD as well as to look at potential synergies with angiotensin receptor blockers.
This small study was conducted in 2010 and the abstract was presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.
Look up proteinuria and see why this could be big and why I have been saying that CKD is probably the big indications as they could partner with DaVita or Fresenius and then be bought out.
Nice that there’s still a little bit of optimism left here Sello! :) And Craig you’re doing a great job trying to keep the board “alive”. What are your guys’ thought on revenue, will we see anything of significance this year, or will we have to wait until next year?
News 
Market Data 
Discover 
